Avience Biomedicals IPO Day 3: GMP ₹80 (+₹7)

Welcome back to our daily market pulse on the Avience Biomedicals SME IPO! We’ve officially hit Day 3 of the subscription period, and the excitement is palpable. As of the close of Day 2, the books were still largely open, but the buzz in the market, particularly the Grey Market Premium (GMP), has been telling a different story. Today, we’re diving deep into the subscription figures and what the latest GMP movements suggest for potential investors.

Subscription Status

As of the end of Day 2, the subscription numbers for Avience Biomedicals were showing a flat zero across all categories: Retail, NII (Non-Institutional Investors), and QIB (Qualified Institutional Buyers), with a total subscription also at 0x. Now, before you panic, this is not entirely uncommon for SME IPOs, especially in the initial days. Often, a significant portion of the interest builds up towards the latter half of the subscription window. Retail investors, in particular, tend to wait for more concrete subscription data before committing. The absence of NII and QIB bids at this stage might suggest they’re also observing the market dynamics or have their own internal timelines for evaluation. However, this is where we need to watch closely as Day 3 progresses. A lack of early traction can sometimes be a red flag, but for SMEs, it’s often just a slower start. You’ll want to keep an eye on how these numbers begin to climb today and tomorrow.

GMP Update

Now, let’s talk about the Grey Market Premium (GMP). This is where things get interesting. The current GMP for Avience Biomedicals stands at a robust ₹80. This is a significant jump from yesterday’s ₹73, marking an increase of ₹7. This upward movement in GMP is a very positive signal. It indicates that the market sentiment towards Avience Biomedicals is strengthening. A higher GMP suggests that demand in the unofficial market is outstripping supply, and investors are willing to pay a premium over the issue price of ₹196. If this trend continues, it points towards a potentially strong listing. The expected listing price, based on this GMP, is now around ₹276 (Issue Price ₹196 + GMP ₹80). This is encouraging news for those considering an application.

Should You Apply?

So, the million-dollar question: should you apply for the Avience Biomedicals IPO? The subscription numbers are still to reveal their true story, but the GMP is certainly painting a bright picture. The jump in GMP to ₹80 is a strong indicator of positive market perception and potential listing gains. However, it’s crucial to remember that GMP is an unofficial indicator and doesn’t guarantee listing performance. The SEBI advisor in us always emphasizes a balanced approach. While the GMP is attractive, it’s wise to also look at the company’s fundamentals, its business model, and the overall market conditions. The fact that the IPO period runs until June 22nd gives you ample time to make an informed decision. Don’t rush your application. Keep a close watch on the subscription levels as Day 3 unfolds. If we see significant traction in subscriptions, coupled with this bullish GMP, it could be a compelling opportunity. Remember, the lot size is 600 shares, so factor that into your investment calculation. For more in-depth analysis and all the latest updates, don’t forget to check out the full details. View Full Avience Biomedicals IPO Details